MYUNGMOON Pharm co.,Ltd (017180.KS)
KRW 1860.0
(-0.59%)
KRW 1860.0
(-0.59%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 94.51 Billion KRW | 21.02% |
| 2022 | 78.1 Billion KRW | 25.29% |
| 2021 | 62.33 Billion KRW | 27.24% |
| 2020 | 48.99 Billion KRW | -28.41% |
| 2019 | 68.43 Billion KRW | -8.08% |
| 2018 | 74.45 Billion KRW | -6.0% |
| 2017 | 79.2 Billion KRW | 3.97% |
| 2016 | 76.17 Billion KRW | 21.54% |
| 2015 | 62.67 Billion KRW | 15.72% |
| 2014 | 54.16 Billion KRW | 6.02% |
| 2013 | 51.08 Billion KRW | 9.7% |
| 2012 | 46.57 Billion KRW | -32.37% |
| 2011 | 68.86 Billion KRW | 20.56% |
| 2010 | 57.12 Billion KRW | 7.07% |
| 2009 | 53.34 Billion KRW | 16.89% |
| 2008 | 45.63 Billion KRW | 31.68% |
| 2007 | 34.65 Billion KRW | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 25.82 Billion KRW | 12.6% |
| 2024 Q2 | 25.83 Billion KRW | 0.05% |
| 2023 Q4 | 22.93 Billion KRW | -5.57% |
| 2023 FY | 94.51 Billion KRW | 21.02% |
| 2023 Q3 | 24.28 Billion KRW | -2.61% |
| 2023 Q2 | 24.93 Billion KRW | 8.49% |
| 2023 Q1 | 22.98 Billion KRW | 16.45% |
| 2022 Q2 | 22.81 Billion KRW | 38.4% |
| 2022 FY | 78.1 Billion KRW | 25.29% |
| 2022 Q1 | 16.48 Billion KRW | 16.76% |
| 2022 Q4 | 19.73 Billion KRW | 3.49% |
| 2022 Q3 | 19.07 Billion KRW | -16.39% |
| 2021 Q1 | 15.12 Billion KRW | 20.06% |
| 2021 Q2 | 15.99 Billion KRW | 5.73% |
| 2021 Q4 | 14.11 Billion KRW | -17.44% |
| 2021 Q3 | 17.09 Billion KRW | 6.89% |
| 2021 FY | 62.33 Billion KRW | 27.24% |
| 2020 FY | 48.99 Billion KRW | -28.41% |
| 2020 Q3 | 11.97 Billion KRW | 30.77% |
| 2020 Q4 | 12.6 Billion KRW | 5.2% |
| 2020 Q2 | 9.16 Billion KRW | -39.93% |
| 2020 Q1 | 15.25 Billion KRW | -10.74% |
| 2019 Q4 | 17.08 Billion KRW | -9.9% |
| 2019 FY | 68.43 Billion KRW | -8.08% |
| 2019 Q3 | 18.96 Billion KRW | 20.12% |
| 2019 Q2 | 15.78 Billion KRW | -4.87% |
| 2019 Q1 | 16.59 Billion KRW | -11.73% |
| 2018 Q3 | 18.47 Billion KRW | -2.48% |
| 2018 FY | 74.45 Billion KRW | -6.0% |
| 2018 Q1 | 18.23 Billion KRW | -9.21% |
| 2018 Q2 | 18.94 Billion KRW | 3.86% |
| 2018 Q4 | 18.8 Billion KRW | 1.78% |
| 2017 FY | 79.2 Billion KRW | 3.97% |
| 2017 Q2 | 22.9 Billion KRW | 28.15% |
| 2017 Q3 | 18.33 Billion KRW | -19.97% |
| 2017 Q1 | 17.87 Billion KRW | -6.61% |
| 2017 Q4 | 20.08 Billion KRW | 9.57% |
| 2016 Q1 | 17.79 Billion KRW | 2.95% |
| 2016 Q4 | 19.14 Billion KRW | -4.15% |
| 2016 Q3 | 19.97 Billion KRW | 3.65% |
| 2016 Q2 | 19.26 Billion KRW | 8.24% |
| 2016 FY | 76.17 Billion KRW | 21.54% |
| 2015 Q3 | 17.43 Billion KRW | 27.11% |
| 2015 Q1 | 14.23 Billion KRW | -7.41% |
| 2015 Q4 | 17.28 Billion KRW | -0.86% |
| 2015 Q2 | 13.71 Billion KRW | -3.59% |
| 2015 FY | 62.67 Billion KRW | 15.72% |
| 2014 Q3 | 13.82 Billion KRW | 13.99% |
| 2014 Q2 | 12.12 Billion KRW | -5.57% |
| 2014 Q4 | 15.36 Billion KRW | 11.16% |
| 2014 Q1 | 12.84 Billion KRW | 8.78% |
| 2014 FY | 54.16 Billion KRW | 6.02% |
| 2013 Q3 | 12.87 Billion KRW | -7.09% |
| 2013 FY | 51.08 Billion KRW | 9.7% |
| 2013 Q2 | 13.85 Billion KRW | 10.46% |
| 2013 Q4 | 11.8 Billion KRW | -8.31% |
| 2013 Q1 | 12.54 Billion KRW | 6.21% |
| 2012 Q1 | 15.41 Billion KRW | 0.0% |
| 2012 FY | 46.57 Billion KRW | -32.37% |
| 2012 Q2 | 7.92 Billion KRW | -48.56% |
| 2012 Q3 | 11.09 Billion KRW | 39.86% |
| 2012 Q4 | 11.81 Billion KRW | 6.51% |
| 2011 Q1 | 17.9 Billion KRW | 0.0% |
| 2011 Q3 | 16.34 Billion KRW | -3.31% |
| 2011 FY | 68.86 Billion KRW | 20.56% |
| 2011 Q4 | - KRW | -100.0% |
| 2011 Q2 | 16.9 Billion KRW | -5.6% |
| 2010 Q1 | 13.2 Billion KRW | 0.0% |
| 2010 Q3 | 12.55 Billion KRW | -10.69% |
| 2010 FY | 57.12 Billion KRW | 7.07% |
| 2010 Q4 | - KRW | -100.0% |
| 2010 Q2 | 14.06 Billion KRW | 6.5% |
| 2009 Q3 | 13 Billion KRW | -2.6% |
| 2009 Q4 | - KRW | -100.0% |
| 2009 FY | 53.34 Billion KRW | 16.89% |
| 2009 Q1 | 12.58 Billion KRW | 3.6% |
| 2009 Q2 | 13.35 Billion KRW | 6.14% |
| 2008 Q3 | 9.61 Billion KRW | -24.98% |
| 2008 Q4 | 12.14 Billion KRW | 26.31% |
| 2008 Q2 | 12.81 Billion KRW | 0.0% |
| 2008 FY | 45.63 Billion KRW | 31.68% |
| 2007 FY | 34.65 Billion KRW | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 46.5 Billion KRW | -103.237% |
| Dong-A Socio Holdings Co., Ltd. | 364.1 Billion KRW | 74.042% |
| Ildong Holdings Co., Ltd. | 198.88 Billion KRW | 52.478% |
| HANDOK Inc. | 151.36 Billion KRW | 37.559% |
| Kukje Pharma Co., Ltd. | 67.22 Billion KRW | -40.597% |
| Yuhan Corporation | 564.5 Billion KRW | 83.257% |
| Dong-A ST Co., Ltd. | 322.21 Billion KRW | 70.667% |
| SAMSUNG PHARM. Co., LTD. | 23.74 Billion KRW | -298.009% |
| Hanmi Pharm. Co., Ltd. | 835.85 Billion KRW | 88.692% |
| Hanall Biopharma Co.,Ltd | 75.03 Billion KRW | -25.954% |
| Ilyang Pharmaceutical Co.,Ltd | 198.96 Billion KRW | 52.496% |
| Dong Sung Bio Pharm.Co.,Ltd. | 40.64 Billion KRW | -132.513% |
| Hana Pharm Co., Ltd. | 140.85 Billion KRW | 32.899% |
| Yuyu Pharma, Inc. | 46.5 Billion KRW | -103.237% |
| Ilsung Pharmaceuticals Co., Ltd. | 34.71 Billion KRW | -172.255% |
| REYON Pharmaceutical Co., Ltd. | 76.81 Billion KRW | -23.038% |
| Aprogen pharmaceuticals,Inc. | -12.04 Billion KRW | 884.647% |
| JW Holdings Corporation | 446.15 Billion KRW | 78.816% |
| Ildong Pharmaceutical Co., Ltd. | 207.53 Billion KRW | 54.459% |
| Chong Kun Dang Pharmaceutical Corp. | 655.34 Billion KRW | 85.578% |
| JW Pharmaceutical Corporation | 335.67 Billion KRW | 71.843% |
| Shin Poong Pharm.Co.,Ltd. | 78.61 Billion KRW | -20.218% |
| Hyundai Pharmaceutical Co., Ltd. | 75.23 Billion KRW | -25.622% |
| Samil Pharmaceutical Co.,Ltd | 72.21 Billion KRW | -30.887% |
| Jeil Pharmaceutical Co.,Ltd | 183.81 Billion KRW | 48.581% |
| Yuyu Pharma, Inc. | 46.5 Billion KRW | -103.237% |
| Kwang Dong Pharmaceutical Co., Ltd. | 295.11 Billion KRW | 67.974% |
| Daewoong pharmaceutical Co.,Ltd | 681.55 Billion KRW | 86.132% |
| JW Pharmaceutical Corporation | 335.67 Billion KRW | 71.843% |
| Yuhan Corporation | 564.5 Billion KRW | 83.257% |
| Jeil Pharma Holdings Inc | 201.82 Billion KRW | 53.169% |
| Yungjin Pharm. Co., Ltd. | 70.93 Billion KRW | -33.235% |
| Suheung Co., Ltd. | 99.02 Billion KRW | 4.556% |
| JW Pharmaceutical Corporation | 335.67 Billion KRW | 71.843% |
| Samjin Pharmaceuticals Co., Ltd. | 145.89 Billion KRW | 35.215% |
| Korea United Pharm Inc. | 173.48 Billion KRW | 45.52% |
| CKD Bio Corp. | 5.01 Billion KRW | -1786.423% |
| Daewon Pharmaceutical Co., Ltd. | 254.23 Billion KRW | 62.823% |
| Dongwha Pharm.Co.,Ltd | 184.12 Billion KRW | 48.668% |
| Whan In Pharm Co.,Ltd. | 98.12 Billion KRW | 3.679% |
| Shin Poong Pharm.Co.,Ltd. | 78.61 Billion KRW | -20.218% |
| Chong Kun Dang Holdings Corp. | 371.49 Billion KRW | 74.558% |
| Boryung Corporation | 333.26 Billion KRW | 71.64% |
| Bukwang Pharmaceutical Co., Ltd. | 50.04 Billion KRW | -88.859% |
| Ilyang Pharmaceutical Co.,Ltd | 198.96 Billion KRW | 52.496% |
| JW Lifescience Corporation | 51.32 Billion KRW | -84.151% |